Metastatic Breast Cancer

An Itovebi regimen demonstrated significantly longer progression-free survival compared with placebo in some with metastatic breast cancer.

Trodelvy shows effectiveness in real-world breast cancer treatment, even after receiving Enhertu therapy.

An expert discussed the importance of biomarkers in guiding treatment decisions for patients with metastatic breast cancer.

The Food and Drug Administration (FDA) has approved Itovebi (inavolisib) with Ibrance (palbociclib) and Faslodex (fulvestrant) for certain patients with advanced or metastatic breast cancer.

Martha Carlson shares her experience of overcoming her fears and embarking on a whitewater rafting adventure despite her stage 4 cancer diagnosis.

Patients with HER2-positive metastatic breast cancer may consider related side effects and quality of life outcomes when choosing treatments.

Enhertu improved the time it took for patients with a breast cancer subset to experience worsening pain and other symptoms, without affecting overall quality of life.

Through communication and education, patients with metastatic breast cancer may be able to balance treatment with quality of life.

Enhertu also improved the time to deterioration for pain and other factors in patients with HR-positive, HER2-low and -ultralow metastatic breast cancer.

A patient with metastatic breast cancer confronts financial toxicity and finds a little glimmer of hope through donating cancer drugs.

Two breast oncologists responded to frequently asked questions about metastatic breast cancer.

A patient with metastatic breast cancer finds that sometimes a single small step leads to unexpected improvement.

Annie Bond, a comedian and survivor of metastatic breast cancer, started making videos on social media to cultivate a community she needed after her diagnosis.

The FDA will speed up their review of Enhertu for HR-positive, HER2-low/ultralow advanced breast cancer that cannot be removed via surgery.

An expert explained the importance of understanding different subtypes of metastatic breast cancer and available treatment options based on biomarker testing.

From “Top Chef’” Shirley Chung and comedian Christina Pazsitzky announcing their diagnoses to Erica Ash’s death from the disease, here is what’s happening in the oncology space this week.

Here are answers to 10 questions patients asked at the CURE® Educated Patient® Metastatic Breast Cancer Summit about scans, treatment and clinical trials.

I’m approaching 10 years with stage 4 breast cancer, and this question tops the “most asked” list.

Before enrolling in a clinical trial for metastatic breast cancer, it’s important to know which are best suited for each individual, an expert said.

One specialist explained the ways palliative care, also known as supportive care, can assist patients during a breast cancer journey.

At the CURE® Educated Patient® Breast Cancer Summit, an expert discussed integrative methods that can improve quality of life.

Patients with HR-positive metastatic breast cancer can expect to undergo biomarker testing both at diagnosis and again if the disease progresses.

One expert explained the common side effects at every line of treatment for metastatic HER2-positive breast cancer during the CURE® Educated Patient® Metastatic Breast Cancer Summit.

Having my metastatic breast cancer experience turned into a piece of art was such a meaningful opportunity.

Having social media platforms to share breast cancer experiences changes the narrative for others who may empathize, a survivor and advocate said.

Enhertu lengthened the time to progression in patients with HR-positive, HER2-low or -ultralow metastatic breast cancer.

The Food and Drug Administration granted a breakthrough therapy designation to inavolisib plus Ibrance and fulvestrant for HR-positive, HER2-negative locally advanced or metastatic breast cancer.

When I received news of a fellow blogger’s demise, I was heartbroken.

After seeing how palliative care helped me through cancer, I now advocate for these services to other patients.

The FDA has approved Hercessi for the adjuvant treatment of HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.